Increase speed to market, enhance asset utilization 
and cut production costs through real time product release

December 06 - 08, 2022 | Free Pharma IQ Online Event

Day One - 1 December 2021

9:00 am - 9:45 am EST What Strategies are being Utilised to Reduce Production Cycle Times by 50%

Juan Colberg - Senior Director, Pfizer

This session will address:

• How Pfizer is driving the implementation of flow processes into drug substance manufacture 

• Building modular and the challenges that are currently being overcome and addressed  

• What does the industry standardized approach and landscape look like from a Pfizer perspective? 

• Understanding how to leverage automation integration

• How can strategies be implemented to enhance manufacturing at significantly reduced costs and better quality?

• What future action is Pfizer taking to ensure new facility integration to reduce cycle times further


img

Juan Colberg

Senior Director
Pfizer




Joy Xiaohui Chen

Senior Application Engineer
Entegris

img

Cari Sadowski

Principal Scientist
FUJIFILM Diosynth Biotechnologies

11:00 am - 11:45 am EST Advanced Analytics for Process Manufacturing Data

Truly flexible manufacturing requires continual access to real-time process data for greater understanding, ongoing optimisation and the ability to rapidly respond when unexpected events occur and effective PAT implementations can result in increased quality, faster product release, reduced cycle times and lower labor and energy costs. This session will address:


• Utilising real-time monitors and employing rigorous predictive maintenance strategies and tools

• Embracing an analytics culture so organisations can seize the opportunities to create value from their big data

• Assessing the needs of modularity, configuration changes, data management and automation 

12:00 pm - 12:45 pm EST Developing a Safe Strategy to Boost the Collaborative Adoption of Continuous Manufacturing

Atul Dubey - Principal Investigator (Director), Continuous Manufacturing, US Pharmacopeia

This session will look to address: 

• How do we ensure that everyone who wants to adopt advanced manufacturing knows how to do so?

• Discussing how we are developing standards and processes that are reliable and safe to ensure the monitoring of product quality? 

• How is the USP looking to improve processes and monitoring of reactions which could impact on the supply chain 

• What work is the USP carrying out to update existing standards and also assessing more operations to be standardised to improve overall process optimisation? 

• What does the Gov funding and collaborative approach within pharma mean long-term to the accessibility of quality medicines? 

• How do these partnerships, for example with Phlow Corp help industry to adopt tech safely? 

• When it comes to USP’s initiative around Continuous Manufacturing, what is USP doing to bridge the skills gap or education surrounding the concepts of Continuous Process Manufacturing? 


img

Atul Dubey

Principal Investigator (Director), Continuous Manufacturing
US Pharmacopeia